Skip to main
TNDM
TNDM logo

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 30 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 27%
Sell 3%
Strong Sell 3%

Bulls say

Tandem Diabetes Care is poised for substantial growth, as indicated by its recently reported top-line revenue of $252.4 million, reflecting a year-over-year increase of 20.6%, which exceeded consensus expectations. The company’s product pipeline, particularly the launch of the Mobi pump and FDA clearance for Type 2 diabetes patients, positions it to capitalize on a significantly expanded market, with more than double the addressable population. Furthermore, high customer satisfaction is driving strong retention rates and consistent growth, underlining Tandem's potential to maintain double-digit revenue growth in the MedTech sector.

Bears say

Tandem Diabetes Care has faced significant operating losses since its inception, raising concerns about its ability to achieve sustained profitability. The company reported weaker-than-expected sales trends and provided underwhelming 2025 guidance, indicating potential challenges such as slower market expansion and competition that may hinder growth. Additionally, margins fell short of consensus expectations while uncertainties in reimbursement and geopolitical conditions further complicate future financial performance.

TNDM has been analyzed by 30 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 27% suggest Holding, 3% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 30 analysts, TNDM has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.